3,956 Shares in Solventum Co. (NYSE:SOLV) Bought by DSG Capital Advisors LLC

DSG Capital Advisors LLC purchased a new stake in Solventum Co. (NYSE:SOLV - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,956 shares of the company's stock, valued at approximately $261,000.

Several other large investors have also modified their holdings of the business. Exchange Traded Concepts LLC lifted its stake in shares of Solventum by 1,593.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 14,650 shares of the company's stock valued at $968,000 after buying an additional 13,785 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Solventum during the fourth quarter valued at approximately $58,000. Blue Trust Inc. lifted its stake in shares of Solventum by 2.1% during the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company's stock valued at $549,000 after buying an additional 161 shares during the period. KBC Group NV lifted its stake in shares of Solventum by 725.3% during the fourth quarter. KBC Group NV now owns 234,933 shares of the company's stock valued at $15,520,000 after buying an additional 206,466 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its stake in shares of Solventum by 3.1% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 28,694 shares of the company's stock valued at $1,896,000 after buying an additional 868 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Wells Fargo & Company increased their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Mizuho increased their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Bank of America increased their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Finally, Morgan Stanley increased their price target on shares of Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research note on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Solventum currently has an average rating of "Hold" and a consensus price target of $80.29.

Solventum Price Performance

Shares of NYSE:SOLV traded up $0.43 during trading on Friday, reaching $73.04. The company had a trading volume of 4,073,029 shares, compared to its average volume of 1,245,079. The firm's fifty day moving average is $69.45 and its 200 day moving average is $71.29. The firm has a market capitalization of $12.64 billion and a PE ratio of 33.81. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Solventum (NYSE:SOLV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.15. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.02 billion. During the same quarter in the previous year, the firm earned $2.08 earnings per share. The firm's revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities analysts forecast that Solventum Co. will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.